Codexis (CDXS) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/27/2026
- Wall St set to open higher as pause in US-Iran hostilities lifts sentiment
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Why is Bernstein bullish on memory stocks after Samsung, Nvidia deals?
- Oil prices near one-week low after US, Iran pause fighting over weekend
- Jefferies turns bullish on Ford, GM ahead of earnings, citing stronger margins
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Nvidia in talks with OpenAI to guarantee $250 billion financing for data center, WSJ reports
- Taiwan Semi (TSM) PT Raised to $530 at Needham
- Strategy sells MSTR shares, doesn't buy bitcoin
Codexis Reports First Quarter 2024 Financial Results
May 2, 2024 4:05 PM EDTQ1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance
First Substantial Order for dsRNA Ligase Received from Large Pharma Customer
Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis Manufacturing Platform and will Provide Update at TIDES USA Meeting
REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March... More
